echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > First-line treatment for advanced esophageal cancer: Can the domestic PD-1 eye-catching K drug sit on the top spot?

    First-line treatment for advanced esophageal cancer: Can the domestic PD-1 eye-catching K drug sit on the top spot?

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In recent years, the application of immunotherapy, especially the PD-1 monoclonal antibody, has caused a sea-shaking change in the treatment of advanced esophageal cancer.


    Six months later, great news came from across the ocean.


    However, winning the top spot does not mean being proud.


    KEYNOTE-590 China's cohort expansion was withdrawn due to program modification, the specific reason is unknown.


    In addition, according to the NextClinTrial database, BeiGene, Cinda Bio, Junshi Bio, Fuhong Henlius, and CStone Pharmaceuticals all have a phase 3 clinical trial layout of PD-1/PD-L1 combined with chemotherapy for the first-line treatment of advanced esophageal cancer.


    This team is still in the "honest" immune combination chemotherapy, BMS and Roche directly played a "marriage trick.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.